Literature DB >> 24560517

Surgical ablation for atrial fibrillation for two decades: are the results of new techniques equivalent to the Cox maze III procedure?

John M Stulak1, Rakesh M Suri2, Harold M Burkhart2, Richard C Daly2, Joseph A Dearani2, Kevin L Greason2, Lyle D Joyce2, Soon J Park2, Hartzell V Schaff2.   

Abstract

OBJECTIVES: A significant evolution has occurred in surgical ablation for atrial fibrillation (AF) toward alternate energy sources, lesion sets, and approaches, with the intent of simplifying the Cox maze III operation and maintaining similar outcomes. Because no large comparative studies with long-term follow-up exist, we have reviewed our experience.
METHODS: From January 1993 to January 2011, 1540 patients underwent surgical ablation for AF. The operations were performed in conjunction with repair of congenital heart disease in 351 (30%) and adult-acquired disease in 1189 patients (70%). In the 1189 patients, preoperative AF was paroxysmal in 598 (50%) and persistent in 591 (50%). The energy sources included cut and sew in 521 (44%), cryothermy in 267 (22%), radiofrequency in 262 (22%), and a combination in 139 patients (12%). The lesion sets included biatrial in 810 (68%), isolated pulmonary vein isolation in 269 (23%), and isolated left atrial in 110 (9%). AF ablation was performed during isolated mitral valve surgery in 516 patients (43%).
RESULTS: The median follow-up was 33 months (maximum, 20.3 years), and late rhythm follow-up was available for 80%. The cut and sew Cox maze III procedure was superior at each follow-up interval (P = .01, P = .03, and P < .001). On multivariate analysis, the cut and sew maze procedure was independently associated with less risk of recurrent AF at a follow-up period of 1 to 5 years (hazard ratio, 0.4; 95% confidence interval, 0.24-0.69; P < .001) and >5 years (hazard ratio, 0.23; 95% confidence interval, 0.12-0.42; P < .001) for all patients. When performed during isolated mitral valve surgery, the cut and sew Cox maze III was also independently associated with less risk of recurrent AF at >5 years (hazard ratio, 0.23; 95% confidence interval, 0.08-0.66; P = .007).
CONCLUSIONS: The cut and sew Cox maze III procedure appears to offer significantly greater freedom from AF without antiarrhythmic medications compared with alternate energy sources and lesion sets. Although alternate energy sources offer the advantage of quicker application and the possibility of minimally invasive applications, the Cox maze III operation arguably remains the reference standard for the surgical treatment of AF and should still be considered, especially for patients for whom AF ablation is of critical importance.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24560517     DOI: 10.1016/j.jtcvs.2013.10.084

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

Review 1.  Electrophysiological Perspectives on Hybrid Ablation of Atrial Fibrillation.

Authors:  Faisal F Syed; Hakan Oral
Journal:  J Atr Fibrillation       Date:  2015-12-31

2.  Impact of volume reduction in giant left atrium during surgical ablation of atrial fibrillation.

Authors:  Jae Hyun Kim; Woo Sung Jang; Jae-Bum Kim; Sook Jin Lee
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

3.  Cox-maze III procedure for atrial fibrillation during valve surgery: a single institution experience.

Authors:  Chang-Tian Wang; Lei Zhang; Tao Qin; Zhi-Long Xi; Lei Sun; Hai-Wei Wu; De-Min Li
Journal:  J Cardiothorac Surg       Date:  2020-05-24       Impact factor: 1.637

4.  Late Results of Cox Maze III Procedure in Patients with Atrial Fibrillation Associated with Structural Heart Disease.

Authors:  Gustavo Gir Gomes; Wagner Luis Gali; Alvaro Valentim Lima Sarabanda; Claudio Ribeiro da Cunha; Iruena Moraes Kessler; Fernando Antibas Atik
Journal:  Arq Bras Cardiol       Date:  2017-06-29       Impact factor: 2.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.